Advaxis (NASDAQ: ADXS) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
View Top Employees from Advaxis, Inc.Website | http://www.advaxis.com |
Ticker | ADXS |
Revenue | $6 million |
Funding | $266.4 million |
Employees | 43 (34 on RocketReach) |
Founded | 2002 |
Address | 305 College Rd E, Princeton, New Jersey 08540, US |
Phone | (732) 545-1590 |
Fax | (609) 452-9818 |
Technologies |
JavaScript,
HTML,
PHP
+38 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Drug Manufacturing & Research, Immunotherapy, Pharmaceuticals, Science and Engineering, Drug Discovery, Oncology, Healthcare, Health Diagnostics, Infectious Disease, Health Care, HPV, Pharmaceutical |
Web Rank | 2 Million |
Keywords | Advaxis, Advaxis Phase 3 Clinical, Listeria Monocytogenes Cancer Vaccine Llo, Advaxis Technology, Adxs |
Competitors | AELIX Therapeutics, Morphogenesis, Inc., PDS Biotechnology, Precision Biologics, Scancell Ltd |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 325413 Companies, NAICS Code 32 Companies |
Looking for a particular Advaxis, Inc. employee's phone or email?
The Advaxis, Inc. annual revenue was $6 million in 2023.
34 people are employed at Advaxis, Inc..
Advaxis, Inc. is based in Princeton, New Jersey.
The NAICS codes for Advaxis, Inc. are [3254, 325, 32541, 325413, 32].
The SIC codes for Advaxis, Inc. are [28, 283].